Verisian has raised $5.0M in total across 2 funding rounds.
Verisian's investors include Bowery Capital, Dimension Capital, Octopus Ventures, Seedcamp, SuperSeed, Allen Gannett, Johnny Boufarhat, Mads Jensen, Paul Forster, Robin Klein, William Tunstall-Pedoe, 14Peaks Capital.
Verisian is a UK-based technology company that builds a platform to radically accelerate clinical trial analysis, validation, and regulatory submissions in the pharmaceutical industry. Their product automates and streamlines the clinical trial data analysis process, providing real-time transparency and traceability, which helps researchers, pharmaceutical companies, biotechs, CROs, and regulatory agencies bring safer and more effective drugs to market faster. By eliminating traditional bottlenecks such as double programming and improving the clarity and reliability of clinical data reporting, Verisian addresses the critical problem of lengthy drug approval timelines, ultimately aiming to improve human health outcomes more rapidly[1][2][3].
Verisian was co-founded by Tomás Sabat Stöfsel (CEO), who previously was COO and a founding team member at Vaticle (creators of the open-source database TypeDB), and Henning Kuich (CTO), formerly a Senior Computational Scientist at Bayer Pharmaceuticals. The idea emerged from recognizing the inefficiencies and delays in clinical trial analysis and drug approval processes, despite advances in pharmaceutical innovation. Early traction included securing £1 million in funding led by Seedcamp and other investors, enabling the company to grow its engineering team and develop its core platform, including a “builder” tool to help pharma companies program studies ready for submission[1][4].
Verisian rides the trend of digital transformation and automation in pharmaceutical R&D, particularly in clinical trial data management and regulatory technology (RegTech). The timing is critical as the pharmaceutical industry faces increasing pressure to reduce drug development timelines and costs while maintaining high safety and efficacy standards. Market forces such as growing data complexity, regulatory scrutiny, and demand for faster patient access to therapies favor Verisian’s innovative approach. By enabling real-time, transparent analysis and submission-ready study programming, Verisian influences the broader ecosystem by setting new standards for clinical trial validation and accelerating drug approvals[1][3].
Looking ahead, Verisian is poised to expand its platform capabilities and deepen partnerships with tier-1 pharmaceutical companies. Trends shaping their journey include the increasing adoption of AI and graph-based technologies in healthcare data, regulatory modernization efforts, and the growing emphasis on real-world evidence and data transparency. As Verisian scales, its influence may extend beyond clinical trials into broader pharmaceutical data workflows, potentially becoming a cornerstone technology for faster, safer drug development. Their mission to make drug availability immediate after clinical trials could redefine industry timelines and patient outcomes[1][3].
Verisian has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Seed in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $4.0M Seed | Bowery Capital, Dimension Capital, Octopus Ventures, Seedcamp, SuperSeed, Allen Gannett, Johnny Boufarhat, Mads Jensen, Paul Forster, Robin Klein, William Tunstall-Pedoe | |
| Aug 1, 2023 | $1.0M Seed | 14Peaks Capital, Bowery Capital, Dimension Capital, Molten Ventures, Passion Capital, Rebel Fund, Recode Ventures, #SecretFund, Seedcamp, SuperSeed, Allen Gannett, Charles Delingpole, Christian Reber, Johnny Boufarhat, Luca Ascani, Mads Jensen, Nick Caldwell, Paul Forster, William Tunstall-Pedoe, Youcef Es-skouri |
